



**For Immediate Release**  
**February 13, 2012**

**Contacts:** Steven Grossman, 1-(301) 539-9660  
Margaret Anderson, 202-336-8912

## **Alliance for a Stronger FDA Concerned by President's FY 13 Budget Request for FDA**

-----

### **President Recognizes FDA's Exceptional Mission, But Proposes No Increase in Appropriated Funds**

WASHINGTON, D.C., February 13, 2012 – The Alliance for a Stronger FDA today expressed concern that President Obama's FY 13 budget request for the US Food and Drug Administration did not include an increase in appropriated funding.

The Alliance, which represents all the major stakeholders affected by the FDA, including regulated industry, professional associations, and patient and consumer groups, noted that the President's proposed budget for FDA is \$4.49 billion. Of that, only \$2.5 billion is from appropriated funds, the same as FY 12, with the remainder coming from significant increases in user fees paid by the various regulated industries.

"The FDA's essential role in protecting public health continues to grow to meet the demands of our time. With no other agency as fallback, we believe that FDA's funding should be increased to reflect the agency's vast responsibilities and increased workload," said Margaret Anderson, President of the Alliance and Executive Director of FasterCures. "Inadequate funding for the FDA has real and immediate consequences as it jeopardizes the public health."

She continued: "The key thing to watch is the actual budget appropriation, and not the user fees. It is the appropriated dollars that are used to run the agency and pay for overseeing imported goods, assuring food safety, and stimulating medical product innovation and ensuring safety, as well as dealing with inevitable crises, such as seafood safety during the Gulf oil spill."

"In this year of austerity, we appreciate that the President has proposed the same funding for FDA, even while many other agencies have been cut. However, this is not enough when the FDA mission is expanding and the agency is providing services and protections that Americans value," added Diane Dorman, Vice President of the Alliance and Senior Vice President for Policy at the National Organization for Rare Disorders. "The Alliance, which represents the entire FDA stakeholder community, is concerned that inadequate funding for the FDA jeopardizes the public health."

FDA is unusual in that regulated companies pay fees to register manufacturing and other facilities, to process marketing applications for medical products, and to regulate tobacco products. Included in the FY 2013 proposed budget are new fees for generic drugs, biosimilar drug applications, and for food establishment registration.

Anderson noted that FDA not only protects and advances the public health, but also provides an economic benefit to the US. The importance of FDA and its regulated industry to the American economy is detailed in

the Alliance's white paper: [FDA: A Cornerstone of America's Economic Future](http://fdaalliance.files.wordpress.com/2011/03/fda_cornerstone_of_american_economy_finalforprint2.pdf).  
([http://fdaalliance.files.wordpress.com/2011/03/fda\\_cornerstone\\_of\\_american\\_economy\\_finalforprint2.pdf](http://fdaalliance.files.wordpress.com/2011/03/fda_cornerstone_of_american_economy_finalforprint2.pdf))

The Alliance's 200 members are comprised of consumer, patient, professional and research groups, companies, trade associations, and individuals who support increased appropriated funding for FDA. The Alliance is the only multi-stakeholder group that advocates for increasing resources at FDA to match the agency's responsibilities. More information about the Alliance can be found at [www.StrengthenFDA.org](http://www.StrengthenFDA.org).

###

UPDATED FEBRUARY 13, 2012

## President's FY 13 Request for Budget Authority Appropriations for FDA

Compared to FY 10, FY 11 and FY 12

Function Note: budget authority only, by center	FY 10 Final	FY11 Final CR	FY 12 Final	FY 13 President's Request 2/13/12
Food	\$ 784 million	\$ 836 million	\$ 866 million	<b>\$ 855 million</b>
Human Drugs	\$ 465 million	\$ 477 million	\$ 478 million	<b>\$ 473 million</b>
Biologics	\$ 206 million	\$ 212 million	\$ 212 million	<b>\$ 210 million</b>
Animal Drugs/Feed	\$ 135 million	\$ 139 million	\$ 138 million	<b>\$ 136 million</b>
Devices & Radiological Health	\$ 315 million	\$ 322 million	\$ 323 million	<b>\$ 319 million</b>
Natl. Ctr. For Toxicological Research	\$ 59 million	\$ 61 million	\$ 60 million	<b>\$ 59 million</b>
HQ, Officer. of Commissioner & Other	\$ 144 million	\$ 150 million	\$ 154 million	<b>\$ 163 million</b>
Rent & Facilities Cost	\$ 237 million	\$ 250 million	\$ 266 million	<b>\$ 297 million *</b>
<b>SUBTOTAL, Salaries and Expenses</b>	<b>\$ 2.345 billion</b>	<b>\$ 2.447 billion</b>	<b>\$ 2.497 billion</b>	<b>\$ 2.512 billion</b>
Building and Facilities Repair	\$ 16 million	\$ 10 million	\$ 9 million	<b>\$ 5 million</b>
<b>All BA appropriations Total (no user fees)</b>	<b>\$ 2.361 billion</b>	<b>\$2.457 billion</b>	<b>\$ 2.506 billion</b>	<b>\$ 2.517 billion</b>

\* Includes + \$17 million for White Oak consolidation

- Chart does not include user fees.
- Some variation due to rounding.

**Steven Grossman**, phone: (301) 539-9660 email: [sgrossman@StrengthenFDA.org](mailto:sgrossman@StrengthenFDA.org)

**Ladd Wiley**, phone: (202) 887-4083 email: [lwiley@StrengthenFDA.org](mailto:lwiley@StrengthenFDA.org)